Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2414971
Max Phase: Preclinical
Molecular Formula: C23H24FN7O4S
Molecular Weight: 513.56
Molecule Type: Small molecule
Associated Items:
ID: ALA2414971
Max Phase: Preclinical
Molecular Formula: C23H24FN7O4S
Molecular Weight: 513.56
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(NCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1cccs1
Standard InChI: InChI=1S/C23H24FN7O4S/c24-18-12-16(31-15-17(35-23(31)34)14-30-6-5-26-27-30)3-4-19(18)28-7-9-29(10-8-28)21(32)13-25-22(33)20-2-1-11-36-20/h1-6,11-12,17H,7-10,13-15H2,(H,25,33)/t17-/m0/s1
Standard InChI Key: VGMJOLBOXHJWQK-KRWDZBQOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 513.56 | Molecular Weight (Monoisotopic): 513.1595 | AlogP: 1.58 | #Rotatable Bonds: 7 |
Polar Surface Area: 112.90 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 0.78 | CX LogP: 1.42 | CX LogD: 1.42 |
Aromatic Rings: 3 | Heavy Atoms: 36 | QED Weighted: 0.51 | Np Likeness Score: -2.35 |
1. Phillips OA, Udo EE, Abdel-Hamid ME, Varghese R.. (2013) Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones., 66 [PMID:23811087] [10.1016/j.ejmech.2013.05.041] |
2. Fernandes GFS, Scarim CB, Kim SH, Wu J, Castagnolo D.. (2023) Oxazolidinones as versatile scaffolds in medicinal chemistry., 14 (5): [PMID:37252095] [10.1039/d2md00415a] |
Source(1):